Biotech Startups

Intellia Therapeutics develops in vivo and ex vivo CRISPR/Cas9 gene editing therapies aimed at treating the root causes of severe genetic diseases, with lead candidates for hereditary angioedema and ATTR amyloidosis. The company operates as a clinical-stage biopharmaceutical company pursuing potentially curative treatments from discovery through commercialization.

7 investors

Invitae provides genetic testing services to patients and clinicians across the United States, offering broad test offerings and genetic counseling to inform health decisions at every stage of life. Now part of Labcorp, the company leverages a nationwide network of patient service centers and coverage by most health plans to make genetic testing more accessible.

7 investors

Johnson & Johnson develops prescription medicines and medical technology across areas including oncology, immunology, neuroscience, cardiopulmonary, cardiovascular, orthopaedics, surgery, and vision. Its two main businesses, Innovative Medicine and MedTech, focus on treating complex diseases through science-based drugs and less invasive, personalized medical devices.

7 investors

Kano Therapeutics develops circular single-stranded DNA (cssDNA) as a genetic payload for gene-editing and other DNA-based therapies, offering an alternative to viral vectors and double-stranded DNA. It manufactures cssDNA via industrial fermentation and licenses and supplies the payload to therapeutic developers through integrated partnerships spanning discovery to GMP.

7 investors

Kenota (formerly ExVivo Labs) develops diagnostic technology for disease testing. The company operates in the healthcare and diagnostics industry.

7 investors

Kingdom Superculture develops functional health ingredients derived from natural microbes, targeting consumers seeking effective nutritional and health products. The company combines microbiology expertise with data science to engineer microbe-based ingredients.

7 investors

Kytopen develops non-viral gene delivery technology called Flowfect that combines fluid flow with electric fields to deliver payloads such as mRNA, DNA, and CRISPR Cas9 RNP into cells for high-throughput transfection. Its platforms serve cell therapy researchers and developers, supporting drug discovery, process optimization, and scaling from small-volume experiments to manufacturing.

7 investors

La Vie Foods produces plant-based meat substitutes including bacon, ham, sausage, meatballs, sandwiches, and tofu for consumers seeking vegetarian and vegan alternatives. The company operates in the foodtech sector with products designed as direct replacements for traditional meat products.

7 investors

Labviva is an AI-native procurement platform that unifies the life sciences supply chain, helping research organizations optimize procurement processes and reduce costs. The platform serves life sciences companies and research institutions by automating lab operations and inventory management.

7 investors

Latent Labs develops generative AI models for protein design and builds biological platforms to validate AI-driven designs. The company works at the intersection of generative AI, engineering, and biology.

7 investors

Luminopia is an FDA-cleared binocular therapy for amblyopia in children aged 4-12 that uses a VR headset to stream the child's favorite TV shows as treatment, replacing traditional eye patches. Clinically tested in US trials, the therapy is prescribed by doctors and requires one hour of use per day, six days a week.

7 investors

Lycos PBC develops investigational psychedelic-based therapeutics to treat mental health conditions, with an initial focus on post-traumatic stress disorder. The company applies decades of evidence-based research to create new therapeutic approaches for patients with unmet mental healthcare needs.

7 investors

Marama Labs develops optical spectroscopy instruments for life-sciences research, leveraging surface-enhanced Raman spectroscopy and nanoparticle characterization technology. The company serves research institutions and scientific laboratories requiring advanced instrumentation for molecular analysis.

7 investors

Maxwell Biosciences develops therapeutics aimed at treating infectious diseases. The company works with research and defense institutions on biodefense and antimicrobial-related work.

7 investors

Melt&Marble uses precision fermentation, microbial metabolic engineering, and synthetic biology to produce fats and ingredients aimed at creating more sustainable food products. The company develops and scales bioprocesses to translate its scientific work into large-scale, cost-effective manufacturing for the food and agri-food industry.

7 investors

Memo Therapeutics develops therapeutic antibodies targeting viral infections to improve treatment outcomes for patients with conditions like BKPyV infection in kidney transplant recipients and oncological viral diseases. The company is a late-stage biotech enterprise collaborating with academic institutions and pharmaceutical partners to advance its pipeline.

7 investors

Menten AI develops generative AI software to design cyclic peptide therapeutics for drug targets beyond the reach of conventional small molecules and biologics. The company partners with major pharmaceutical firms to accelerate preclinical drug discovery.

7 investors

Merge Labs is a research lab developing brain-computer interfaces that connect with neurons using molecules instead of electrodes and non-invasive modalities like ultrasound, integrated with AI. It aims initially to help patients with injury or disease and later to broadly advance human capability.

7 investors

San Diego clinical-stage biopharma developing non-bile acid FXR agonists for liver and gastrointestinal diseases.

7 investors

Mineralys Therapeutics is a clinical-stage pharmaceutical company developing lorundrostat, a treatment targeting dysregulated aldosterone. It focuses on cardio-renal-metabolic diseases, including hypertension and chronic kidney disease.

7 investors

MinervaX is a biotech company developing prophylactic vaccines, with therapeutic focus areas including immunology and infectious disease. Its work spans vaccine discovery through late-stage clinical development and regulatory approval.

7 investors

Minoryx is a registration-stage biotech company developing novel therapies for severe, orphan genetic diseases of the central nervous system, with a lead compound (leriglitazone) in clinical trials for conditions including cerebral adrenoleukodystrophy, Friedreich's Ataxia, and Rett syndrome.

7 investors

Automates complex biological protocols in a compact cartridge-based system for genomic sequencing

7 investors

Mirum Pharmaceuticals is a biopharmaceutical company that develops and delivers therapies for people living with rare diseases. It operates in the U.S. and Europe, engaging with healthcare professionals, patients, and payers within applicable regulatory frameworks.

7 investors